Biotek-snakken — April 2024
-
ImmunityBio's bladder cancer therapy wins FDA approval
The US Food and Drug Administration has approved ImmunityBio's (IBRX) bladder cancer therapy, a significant milestone for the company. ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong, joins Market Domination alongside Yahoo Finance's health reporter Anjalee Khemlani to discuss the company's plans following this pivotal approval. Soon-Shiong says that Anktiva will be "the next generation of immuno-therapy." He claims the drug is the first of its kind to "generate complete remission that's completely durable" for 47 months and longer. Soon-Shiong believes the drug will serve as "a backbone" to "checkpoint inhibitors," a class of immunotherapy drugs. He envisions the drug's potential to target cancers regardless of their location within the body, describing it as "an opportunity to use this as a fundamental platform across all tumor types." Soon-Shiong says he, alongside other entities, collectively invested around $400 million in the company when the drug was first rejected. He further notes that additional investments totaling $100 million are forthcoming, stating, "the company is stable in terms of cash capabilities,"— hoping for a commercial launch of Anktiva in May. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith
Yahoo Finance (finance.yahoo.com)
-
Calliditas: Supportive headline results from the Open Label Extension study
"Our Base Case is SEK 270 with a Bull case of SEK 390 and a Bear case of SEK 90."
-
Godmorgen
-
Har fedmeaktierne tabt momentum?
https://www.nordnet.dk/blog/har-fedmeaktierne-tabt-momentum/?utm_source=ACS&utm_medium=email&utm_campaign=DK_nyhedsbrev_uge17_2024 -
Calliditas: Intervju med vd Renée Aguiar-Lucander (RESEARCH INTERVIEW 2024-04-26)
"Redeye har intervjuat Calliditas VD, Renée Aguiar-Lucander, för ett samtal om utsikterna för Tarpeyo."
-
I
s Viking Therapeutics Incredibly Undervalued? https://www.proinvestor.com/investornyt/1151566/is-viking-therapeutics-incredibly-undervalued -
AQST fandt jeg her i chattet, for noget tid siden! IBRX fandt jeg så ved hjælp af AQST; IBRX opfører sig fuldstændigt som finger i sin tid, så passede mig fint - medicin aner jeg intet om - men short mener jeg godt jeg kan gennemskue, blot firmaet har et potentiale - som finger - men vedr. finger mener kapitalen (bankerne) åbenbart ikke at biometiske aflæsning er noget der skal satses på, nå tilbage til IBRX; her er nemlig også satset en hel del short? IBRX fortsætter vist op igen i dag!
-
IBRX og AQST har nu begge en FDA godkendelse bag sig - så mon ikke at begge stiger fra nu af? IBRX har så den fordel at kommer prisen IKKE ned i denne uge, vil shorts nok blive presset til dækning, og vist mere end 50 mil. sat i short i IBRX, og det er interessant!
-
Er noteringen på www.boerse.de/ (IBRX) stoppet her kl. 08:10, der opdateres ikke længere åbenbart (den her observation er absolut et skud i tågen? Jeg bruger den børs yderst sjældent)? Er det for sent at komme med i IBRX? Nej ikke hvis kursen holder i ugen der går? Set i lyset af den store mængde shorts? Min fortolkning?
-
OK Proinvestor lagde teksten ud i et link? Her er så det gyldige link: https://www.boerse.de/aktien/NANTKWEST-Aktie/US45256X1037
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind